PubRank

S Rodenhuis

Author PubWeight™ 115.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998 3.67
2 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003 3.06
3 Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987 3.04
4 [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. Ned Tijdschr Geneeskd 2006 2.65
5 Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005 2.39
6 Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002 1.80
7 Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. Ann Oncol 2002 1.78
8 Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000 1.70
9 The molecular genetics of human lung cancer. Eur Respir J 1989 1.64
10 Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991 1.64
11 K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993 1.57
12 Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994 1.56
13 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003 1.50
14 Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991 1.47
15 At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol 1999 1.41
16 The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010 1.38
17 [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. Ned Tijdschr Geneeskd 1993 1.38
18 Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 2002 1.37
19 An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2010 1.35
20 Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998 1.35
21 Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol 1984 1.23
22 Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003 1.19
23 Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013 1.17
24 High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006 1.16
25 Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res Treat 1999 1.16
26 Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2010 1.15
27 C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994 1.13
28 Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2011 1.12
29 Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006 1.12
30 Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993 1.07
31 Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. Blood 1986 1.06
32 The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol 1998 1.06
33 Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2012 1.05
34 Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 2013 1.05
35 Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 1999 1.05
36 Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol 2012 1.04
37 Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993 1.04
38 High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 1990 1.03
39 Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991 0.99
40 A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1992 0.99
41 In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 2001 0.98
42 Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 1995 0.98
43 Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 1988 0.96
44 A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 2001 0.94
45 Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995 0.94
46 Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999 0.94
47 Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. Eur J Surg Oncol 1994 0.94
48 N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications. Genes Chromosomes Cancer 1995 0.94
49 Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin. Thorax 1984 0.93
50 Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000 0.93
51 The ras gene family in human non-small-cell lung cancer. J Natl Cancer Inst Monogr 1992 0.93
52 The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs 2000 0.92
53 High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 1995 0.92
54 EAP in advanced gastric cancer. J Clin Oncol 1990 0.91
55 Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 2001 0.91
56 Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol 2012 0.90
57 A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer 1993 0.90
58 Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000 0.90
59 High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995 0.89
60 Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. J Clin Oncol 2002 0.89
61 Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer 2009 0.88
62 Invasive aspergillosis complicated by subclavian artery occlusion and costal osteomyelitis after autologous bone marrow transplantation. Thorax 1992 0.87
63 Prognostic factors in NSCLC. Recent experiences. Lung Cancer 1995 0.87
64 Growth factors in human ovarian cancer. Cancer Treat Rev 1997 0.85
65 Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol 2000 0.84
66 Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991 0.84
67 Breast cancer studies in The Netherlands. Lancet 1996 0.84
68 The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 1995 0.84
69 Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann Oncol 1993 0.84
70 Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992 0.83
71 Association of H-ras mutations with adenocarcinomas of the parotid gland. Int J Cancer 1994 0.83
72 Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996 0.83
73 Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl 1998 0.83
74 Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997 0.83
75 A search for new metabolites of N,N',N''-triethylenethiophosphoramide. Cancer Res 1999 0.83
76 Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. Arthritis Rheum 1987 0.82
77 Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia. N Engl J Med 1985 0.82
78 Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002 0.82
79 Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995 0.81
80 Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. Anticancer Res 2003 0.81
81 Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study. Cancer Chemother Pharmacol 1990 0.80
82 Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. Br J Clin Pharmacol 2001 0.80
83 The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. Eur J Cancer 1996 0.80
84 Sampling technique from central venous catheters proves critical for pharmacokinetic studies. Ther Drug Monit 1999 0.80
85 Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995 0.80
86 Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996 0.80
87 Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 1996 0.79
88 Absence of ras gene mutations in early gastric carcinomas. Gut 1995 0.79
89 Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. Br J Cancer 1989 0.79
90 Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000 0.79
91 A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. Br J Cancer 1992 0.79
92 Early onset of oral aphthous ulcers with weekly docetaxel. Neth J Med 2005 0.78
93 Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Eur J Clin Pharmacol 2001 0.78
94 Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br J Cancer 1996 0.78
95 Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001 0.78
96 Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol 1997 0.78
97 Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 2003 0.78
98 Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990 0.78
99 Inefficacy of plasma exchange in cold agglutinin hemolytic anemia--a case study. Vox Sang 1985 0.77
100 [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. Ned Tijdschr Geneeskd 2008 0.77
101 The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure. Breast Cancer Res Treat 2015 0.77
102 Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma? Br J Haematol 1985 0.77
103 Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 1994 0.77
104 Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 1986 0.76
105 Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer. Br J Cancer 2013 0.76
106 Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 1991 0.76
107 Third-party payers and breast cancer study. J Clin Oncol 1998 0.75
108 High-dose chemotherapy for breast cancer. Ann Intern Med 1997 0.75
109 Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2003 0.75
110 Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion. Cancer Chemother Pharmacol 1996 0.75
111 Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas. Int J Cancer 1991 0.75
112 Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. J Chromatogr B Biomed Sci Appl 2001 0.75
113 Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man. Cancer Chemother Pharmacol 1983 0.75
114 Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin. Anticancer Drugs 2001 0.75
115 Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'. Cancer Chemother Pharmacol 1983 0.75
116 Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. Dig Surg 2004 0.75
117 Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. Bone Marrow Transplant 2008 0.75
118 A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration. Diagn Mol Pathol 1997 0.75
119 Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. Anticancer Drugs 1999 0.75
120 Effect of cisplatin-containing chemotherapy on lithium serum concentrations. Ann Pharmacother 1992 0.75
121 Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule. Eur J Cancer Clin Oncol 1984 0.75
122 The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid. Cancer Chemother Pharmacol 1994 0.75
123 Oncogenes and human lung cancer. Cancer Treat Res 1989 0.75
124 Peripheral blood stem cell (PBSC) mobilization and transplantation (PSCT) in patients with malignant lymphomas and solid tumors. Int J Artif Organs 1993 0.75
125 Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study. Ann Oncol 1993 0.75
126 A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemother Pharmacol 1999 0.75
127 Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 1997 0.75
128 Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999 0.75
129 Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995 0.75
130 Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients. Eur J Cancer 1997 0.75
131 Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. Eur J Cancer Clin Oncol 1988 0.75
132 Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer. Pathol Biol (Paris) 1992 0.75
133 Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. Cancer Treat Rev 1989 0.75
134 Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours. Anticancer Res 1996 0.75
135 Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Ther Drug Monit 1995 0.75
136 Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions. Ann Oncol 1996 0.75
137 Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989 0.75
138 Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann Oncol 1997 0.75
139 Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF). Neth J Med 1990 0.75
140 Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother Pharmacol 2000 0.75
141 Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography. J Chromatogr B Biomed Sci Appl 1998 0.75
142 Dose-intensive chemotherapy for locally advanced breast cancer. Curr Oncol Rep 1999 0.75
143 Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. Semin Oncol 1992 0.75
144 [A look over the horizon of cancer treatment. The internist]. TVZ 1989 0.75
145 Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer. Eur J Cancer 1993 0.75
146 Clinical pharmacokinetics of (NPAz2)2NSOAz: 'SOAz'. Cancer Chemother Pharmacol 1983 0.75
147 Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Breast Cancer Res Treat 1996 0.75